FDA-Approved Pancreatic Cancer Breakthrough Faces Access Barriers

The FDA's approval of daraxonrasib this year marked a genuine inflection point in pancreatic cancer treatment. For decades, this disease has resisted the kind of incremental progress that other cancers have seen. Pancreatic cancer kills roughly nine out of ten patients within five years of diagnosis. Daraxonrasib, a targeted therapy that works against specific mutations found in pancreatic tumors, showed in clinical trials that it could extend survival meaningfully for patients whose cancers carried those mutations. Oncologists across the country greeted the approval as a breakthrough—the kind of drug that changes what they can actually offer their patients in the exam room.

But approval by the FDA is not the same as access. Within weeks of daraxonrasib reaching the market, patients and their physicians began running into the machinery that sits between a drug's authorization and a patient's ability to actually receive it. Insurance companies requested prior authorization before covering the treatment. Pharmacy benefit managers—the middlemen who negotiate drug prices on behalf of insurers—built restrictive formularies that limited which patients could get the drug and under what conditions. Some patients found themselves denied coverage outright, told by their insurers that they had not yet exhausted cheaper alternatives, even as their tumors progressed.

The barriers were not uniform. Patients with robust insurance coverage, or those wealthy enough to pay out of pocket, could access daraxonrasib relatively quickly. But patients on Medicare, Medicaid, or with high-deductible plans faced delays measured in weeks or months—delays that matter acutely in pancreatic cancer, where time is a resource in genuinely short supply. Some patients never accessed the drug at all. They cycled through the approval process, received denials, appealed, and by the time coverage was granted, their disease had progressed beyond the point where daraxonrasib would help.

David Gandara, an oncologist who has written about the drug's potential, described daraxonrasib as marking a major advance in pancreatic cancer care. The clinical evidence was solid. But he and his colleagues found themselves spending hours on the phone with insurance companies, arguing for their patients' access to a drug the FDA had already deemed safe and effective. The approval process had taken months. The access process, for many patients, was taking longer.

Early research has also suggested that daraxonrasib may hold promise for certain lung cancers, potentially expanding the population of patients who could benefit from the drug. If those findings hold, the access barriers could affect an even larger group of cancer patients. The drug's manufacturer has set a price point that reflects its breakthrough status and limited patient population, but that price—combined with insurance company caution about new, expensive therapies—has created a gap between what medicine can now do and what patients can actually receive.

The approval of daraxonrasib represents real progress in oncology. But it has also exposed a persistent problem in American healthcare: the distance between innovation and access, between what regulators approve and what patients can obtain. For pancreatic cancer patients, that gap is not academic. It is the difference between a chance at extended survival and running out of time.